- Clinical trials show semaglutide produces an average of 15% body weight loss over 68 weeks; tirzepatide reaches up to 22.5% at the highest dose.
- For a 250-pound person, that translates to roughly 37 to 56 pounds on average -- not a ceiling, an average.
- Weight loss is not linear. The first month is slow, months 3 to 6 are the peak rate, and progress levels off into maintenance after month 12.
- Protein intake, sleep, dose adherence, and starting weight all meaningfully affect your individual results.
- Most people regain weight after stopping GLP-1 medication. Continued treatment or a structured maintenance plan is important for keeping results long-term.
How much weight do people actually lose on GLP-1?
On semaglutide, the average is 15% of body weight over 68 weeks. On tirzepatide at the highest dose, the average reaches 22.5% over 72 weeks. For a 250-pound person, that is 37 to 56 pounds. These are trial averages -- your results will depend on dose, adherence, diet, and your own biology.
When people ask how much weight they can lose on GLP-1, they usually want one number. The honest answer is a range, because GLP-1 medications work differently for different people. But the range is genuinely impressive.
The STEP 1 trial, which enrolled nearly 2,000 adults on semaglutide 2.4mg, found average weight loss of 14.9% of body weight over 68 weeks.[1] That is the number you will see cited most often. But averages can obscure what is happening across the distribution. More than one-third of participants in STEP 1 lost 20% or more of their body weight. About 13% lost 30% or more. A meaningful group lost less than 10%.
Tirzepatide raises the ceiling further. In SURMOUNT-1, participants at the 15mg dose lost 22.5% of body weight on average.[5] Forty percent of participants at the highest dose lost 25% or more. These are numbers that, for most of medical history, were only achievable through bariatric surgery.
What does this mean practically? If you weigh 200 pounds, you might expect to lose 30 to 45 pounds on semaglutide, or 35 to 55 pounds on tirzepatide, over the course of 12 to 18 months. If you weigh 280 pounds, those numbers scale proportionally. The medication works on percentages of your starting weight, not a fixed number of pounds.
Month-by-month weight loss timeline
GLP-1 weight loss does not happen all at once. It follows a predictable arc driven by the dose escalation schedule. You start at a low dose to minimize side effects, then increase gradually over several months until you reach the therapeutic dose. Weight loss tracks closely with this escalation.
Here is what most patients experience, based on data from the STEP and SURMOUNT trials and clinical practice:
| Timepoint | Typical Cumulative Loss | What Is Happening |
|---|---|---|
| Month 1 | 3 to 5 lbs | Starting dose, appetite changes beginning. Progress may feel slow. This is normal. |
| Month 2 | 5 to 8 lbs cumulative | Dose increasing. Appetite suppression strengthening. Food thoughts quieting for many patients. |
| Month 3 | 8 to 15 lbs cumulative | Approaching therapeutic dose. Pace of loss accelerating. Most patients feel meaningfully different by now. |
| Month 6 | 20 to 35 lbs cumulative | At or near full therapeutic dose. Peak loss rate. Energy often improves as blood sugar stabilizes. |
| Month 12 | 30 to 50 lbs cumulative | Loss rate slowing. Body reaching a new equilibrium. Lifestyle habits now matter more at the margin. |
| Month 18+ | Maintenance phase | Weight largely stable. Goal shifts to preserving lean mass and sustaining results with continued treatment. |
Progress will not be perfectly linear for you. You will have weeks where the scale barely moves, followed by weeks of faster change. Weight fluctuates with water retention, sleep, stress, and where you are in your menstrual cycle if applicable. The trend over 4 to 6 weeks matters more than any single weigh-in.
"The scale didn't move for two weeks and I thought it wasn't working. Then I lost 4 pounds in one week. The trend over months is what matters."
What the clinical trials actually show
GLP-1 medications have been studied in some of the largest and most rigorous weight management trials ever conducted. The numbers below are not from marketing materials. They are from peer-reviewed publications in the New England Journal of Medicine, JAMA, and The Lancet.
STEP 1: Semaglutide at the standard dose
STEP 1, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity or overweight plus at least one weight-related health condition.[1] Participants on semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks, versus 2.4% in the placebo group. The treatment difference was 12.4 percentage points. More than 86% of semaglutide participants lost at least 5% of body weight. More than 69% lost at least 10%.
STEP 3: Adding behavioral therapy
STEP 3 combined semaglutide 2.4mg with intensive behavioral therapy and an initial low-calorie diet.[3] Average weight loss was 16.0%, modestly higher than STEP 1. This suggests that structured lifestyle support adds incremental benefit on top of the medication, though semaglutide alone still produced the vast majority of the effect.
STEP 5: Two-year results
STEP 5 followed participants for 104 weeks, providing the longest semaglutide data set at time of publication.[4] Average weight loss was 15.2% at two years, demonstrating that results are maintained with continued treatment rather than plateauing and reversing. This is a critical finding: the medication continues to work.
SURMOUNT-1: Tirzepatide raises the bar
SURMOUNT-1, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults without diabetes.[5] At the highest dose of tirzepatide (15mg), participants lost 22.5% of body weight on average over 72 weeks. At 5mg, average loss was 15.0%; at 10mg, it was 19.5%. The study authors noted that weight reductions of this magnitude had not previously been achieved with pharmacological intervention outside of surgery.
SURMOUNT-2: Tirzepatide in people with type 2 diabetes
SURMOUNT-2 showed that people with type 2 diabetes taking tirzepatide lost an average of 15.7% at the 15mg dose over 72 weeks.[6] Weight loss is somewhat lower in people with diabetes, but still clinically meaningful and greater than anything previously available.
The SELECT trial: cardiovascular outcomes
SELECT enrolled 17,604 adults with obesity and established cardiovascular disease but no diabetes.[7] Participants on semaglutide had a 20% lower rate of major cardiovascular events (heart attack, stroke, or cardiovascular death) compared to placebo. The cardiovascular benefit appeared beyond what weight loss alone would explain, suggesting GLP-1 receptors in the heart and blood vessels play a direct protective role.
Ready to see what results are realistic for your starting weight?
Take our free 2-minute quiz. A licensed provider reviews your answers personally.
Take the Free Quiz →What affects your results?
GLP-1 medications are powerful, but they work within the context of your biology and lifestyle. These are the factors with the strongest evidence for affecting individual outcomes.
Starting body weight
Patients with higher starting weights tend to lose more pounds in absolute terms, even when the percentage of body weight lost is similar. If you weigh 300 pounds and lose 15%, that is 45 pounds. If you weigh 180 pounds and lose 15%, that is 27 pounds. Both are significant, but the person with more weight to lose will see larger absolute numbers on the scale.
Dose adherence and reaching therapeutic dose
This is the single biggest controllable factor. GLP-1 medications work at their therapeutic dose. If you stay at a low dose because of side effects or stop taking injections consistently, you will not achieve the results seen in trials. The dose escalation schedule exists to minimize side effects while getting you to the dose that produces meaningful results. Staying with it matters.
Protein intake
During GLP-1-driven weight loss, your body loses both fat and lean muscle mass. The proportion depends heavily on how much protein you eat. Multiple analyses of the STEP trials found that participants who maintained higher protein intakes preserved more muscle mass and achieved better body composition outcomes.[13] Target at least 0.7 to 1.0 grams of protein per pound of goal body weight per day. This is harder than it sounds when your appetite is suppressed, which makes intentional protein tracking important especially in the first few months.
Exercise, especially resistance training
Physical activity amplifies GLP-1 results and, more importantly, protects muscle mass. A 2023 analysis found that participants who combined GLP-1 medications with resistance training lost significantly more fat mass and significantly less muscle mass than those who relied on medication alone.[14] You do not need to become an athlete. Two to three sessions of resistance training per week plus regular walking is enough to make a meaningful difference in body composition.
Sleep quality
Poor sleep raises cortisol, increases ghrelin (the hunger hormone), and blunts the appetite-suppressing effects of GLP-1 medications. Research consistently links short or disrupted sleep with reduced weight loss outcomes. Getting 7 to 9 hours of quality sleep is not optional for people trying to maximize GLP-1 results.
Genetics
GLP-1 receptor gene variants partially explain why some people are "super-responders" who lose 25% or more, while others with similar adherence lose less. Current genetic testing is not refined enough to predict your response before starting treatment. The only reliable way to know how you will respond is to start and measure.
Other medications
Several common medications promote weight gain or blunt weight loss, including some antidepressants (particularly SSRIs and mirtazapine), antipsychotics, certain blood pressure medications, corticosteroids, and some insulin formulations. If you are on any of these, your Kind MD provider can discuss whether alternatives exist and what to expect given your medication history.
Metabolic health baseline
Insulin resistance, thyroid dysfunction, and other metabolic conditions can limit how much weight you lose. Addressing these alongside GLP-1 treatment -- with your primary care physician if needed -- gives you the best foundation for results.
GLP-1 weight loss vs. other methods
Context matters when evaluating any treatment. Here is how GLP-1 medications compare to the other major approaches to weight loss, based on the best available clinical evidence.
| Method | Average Weight Loss | Timeline | Maintenance |
|---|---|---|---|
| GLP-1 (semaglutide) | 15% body weight | 12 to 18 months | Requires continued treatment; weight regain common after stopping |
| GLP-1 (tirzepatide) | 22.5% body weight | 12 to 18 months | Requires continued treatment; weight regain common after stopping |
| Diet and exercise alone | 3 to 5% body weight | 6 to 12 months | High regain rate; 80% or more regain weight within 5 years |
| Bariatric surgery | 25 to 35% body weight | 12 to 24 months | Most effective long-term; some regain occurs after 5 to 10 years |
| Phentermine | 5 to 10% body weight | 3 to 6 months (approved for short-term use only) | Weight regain common after stopping; not approved for long-term use |
| Orlistat | 3 to 5% body weight | 6 to 12 months | GI side effects limit adherence; modest long-term results |
The comparison that surprises most people is GLP-1 medications versus diet and exercise alone. Decades of research show that sustained lifestyle-only weight loss in people with clinical obesity averages 3 to 5% of body weight, with most people regaining the majority within five years.[15] This is not a failure of willpower. It is a physiological response driven by the body's hormonal set point. GLP-1 medications address that set point directly.
Bariatric surgery remains the most effective intervention available in terms of sheer magnitude of weight loss and durability of results. But it involves anesthesia, hospitalization, recovery time, and lifelong dietary changes. For patients who are not surgical candidates or prefer to avoid surgery, tirzepatide's 22.5% average outcome is now approaching surgical territory.
Can you keep the weight off?
This is the question that matters most. The evidence here is clear and honest: stopping GLP-1 medication leads to weight regain for most people, and continuing treatment is the most reliable way to maintain results.
What happens when you stop
The STEP 1 extension study, published in 2022, followed participants who completed the initial 68-week trial for an additional 52 weeks.[4] Those who continued semaglutide maintained their weight loss. Those who stopped and received placebo regained approximately 11.6% of body weight -- returning to within about two-thirds of their original weight within one year. Blood pressure, blood sugar, and cholesterol improved during treatment and largely returned to baseline after stopping.
This pattern mirrors what happens with other chronic disease treatments. High blood pressure returns when you stop blood pressure medication. Cholesterol rises when you stop a statin. Obesity, a chronic condition with a strong biological driver, behaves the same way. Stopping treatment removes the correction, and the biological signals that promote weight regain re-emerge.
What the SELECT trial shows about continued use
The SELECT trial followed 17,604 participants for an average of 34 months on continued semaglutide treatment.[7] Participants maintained weight loss and cardiovascular benefits throughout the trial period. This is the strongest evidence we have that GLP-1 medications continue to work and protect health with long-term use, not just during an initial treatment window.
Lifestyle changes matter most at the margins
The participants who maintain the best results long-term are those who use the appetite suppression that GLP-1 creates to build sustainable eating and movement habits. The medication quiets the biological noise. What you do in that quieter environment -- building consistent protein intake, establishing an exercise routine, improving sleep -- is what gives you the best foundation if you ever reduce or stop the medication.
This is not a guarantee. But patients who build those habits during active GLP-1 treatment tend to regain less weight if treatment is interrupted or discontinued than those who did not make lifestyle changes alongside the medication.
Setting realistic expectations
Not everyone loses 15 to 22%. That is worth saying directly.
Some people lose 5 to 8% on semaglutide and plateau. Some people lose 25 to 30% and feel like an entirely different person. The clinical trial averages are real, but they describe a distribution, not a guarantee for any individual. Your response to GLP-1 medication is partly genetic, partly behavioral, and partly determined by factors that are difficult to predict before starting.
What "realistic" actually means
Realistic for most people is meaningful weight loss that improves health markers, reduces the physical and psychological burden of obesity, and makes daily life feel better. For many patients, that happens even when they lose less than the trial average. A 10% reduction in body weight in a 300-pound person is 30 pounds. That is enough to meaningfully improve blood pressure, blood sugar, sleep quality, joint pain, and mobility.
Progress is also not just the number on the scale. Body composition changes matter as much as weight. Losing 20 pounds of fat while gaining 5 pounds of muscle produces different health outcomes than losing 25 pounds of mixed fat and muscle. This is why protein intake and resistance training are not optional extras but core parts of a GLP-1 treatment plan.
Progress is not linear
Expect plateaus. They are normal and they are not a sign that the medication has stopped working. Your body periodically recalibrates its energy balance during active weight loss, which can produce weeks or even months of minimal scale movement despite continued adherence. These plateaus typically resolve. The key is not to interpret them as failure and abandon treatment prematurely.
Comparing yourself to others is rarely useful
Social media is full of people who lost 40 pounds in 4 months on GLP-1. It is also not showing you the thousands of people who lost 12 pounds over 6 months and are healthier and happier for it, or the ones who needed dose adjustments, or the ones who needed to switch medications. Your outcome is your outcome. The clinical benchmark that matters is whether you are trending in the right direction.
